Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Inetetamab, Pyrotinib and Chemotherapy in Combination for First-line Treatment of HER2-positive Recurrent/Metastatic Breast Cancer

NCT05621434 is registered in ClinicalTrials.gov with Fujian Medical University as lead sponsor.

NCT NCT05621434
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05621434 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Inetetamab, Pyrotinib and Chemotherapy in Combination for First-line Treatment of HER2-positive Recurrent/Metastatic Breast Cancer
Lead sponsor
Fujian Medical University
Phase
Phase 2
Overall status
Unknown status
Start date
December 10, 2022
Completion date
December 10, 2025
Enrollment
63 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive recurrent/metastatic breast cancer